Bone marrow sinusoidal endothelium controls terminal erythroid differentiation and reticulocyte maturation
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA748582 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Within the bone marrow microenvironment, endothelial cells (EC) exert important functions. Arterial EC support hematopoiesis while H-type capillaries induce bone formation. Here, we show that BM sinusoidal EC (BM-SEC) actively control erythropoiesis. Mice with stabilized β-catenin in BM-SEC (Ctnnb1OE-SEC) generated by using a BM-SEC-restricted Cre mouse line (Stab2-iCreF3) develop fatal anemia. While activation of Wnt-signaling in BM-SEC causes an increase in erythroblast subsets (PII-PIV), mature erythroid cells (PV) are reduced indicating impairment of terminal erythroid differentiation/reticulocyte maturation. Transplantation of Ctnnb1OE-SEC hematopoietic stem cells into wildtype recipients confirms lethal anemia to be caused by cell-extrinsic, endothelial-mediated effects. Ctnnb1OE-SEC BM-SEC reveal aberrant sinusoidal differentiation with altered EC gene expression and perisinusoidal ECM deposition and angiocrine dysregulation with de novo endothelial expression of FGF23 and DKK2, elevated in anemia and involved in vascular stabilization, respectively. Our study demonstrates that BM-SEC play an important role in the bone marrow microenvironment in health and disease.
| S-EPMC8630019 | biostudies-literature
Project description:Proteasome inhibition constitutes a cornerstone of multiple myeloma (MM) treatment, with bortezomib, carfilzomib and ixazomib approved for clinical use. We observed a consistent and highly significant increase in the reticulocyte count during treatment with carfilzomib-based regimens in patients with relapsed MM, an observation not made in a matched cohort of bortezomib-treated patients. As this increased reticulocytosis was neither associated with elevated hemoglobin levels nor with hemolysis, we subsequently performed in vitro experiments to unravel the underlying mechanisms of this clinical observation. While carfilzomib did not affect erythroid differentiation of CD34+ hematopoietic progenitor cells, both continuous and pulse exposure to carfilzomib significantly impaired terminal maturation of purified primary reticulocytes towards erythrocytes. These results indicate that carfilzomib significantly impairs terminal erythroid maturation, independent of erythroid commitment, expansion or differentiation. Our results report the first pharmacologically induced delay in erythroid maturation as a mechanism for carfilzomib-induced reticulocytosis in MM patients. Quantitative proteomics using LC-MS/MS were performed to assess whether carfilzomib treatment alters the protein composition of reticulocytes
2020-02-20 | PXD014353 | Pride
Project description:Terminal differentiation of mammalian erythroid progenitors involves 4-5 cell divisions and induction of many erythroid important genes, followed by chromatin and nuclear condensation and enucleation. The protein levels of c-myc (Myc) are reduced dramatically during late stage erythroid maturation, coinciding with cell cycle arrest in G1-phase and enucleation, suggesting possible roles for c-myc in either or both of these processes. Here we demonstrate that ectopic Myc expression affects terminal erythroid maturation in a dose-dependent manner. Expression of Myc at physiological levels did not affect erythroid differentiation or cell cycle shutdown, but specifically blocked erythroid nuclear condensation and enucleation. Myc prevented deacetylation of several lysine residues in histones H3 and H4 that are normally deacetylated during erythroid maturation. When over-expressed at levels higher than the physiological range, Myc blocked erythroid differentiation and the cells continued to proliferate in cytokine-free, serum-containing culture medium with an early erythroblast morphology. These studies reveal an important dose-dependent function of Myc in regulating terminal maturation in mammalian erythroid cells. Our findings further support the emerging notion that Myc regulates chromatin structure by regulating global histone acetylation states. Five groups with three biological replicates in each.
2010-10-13 | E-GEOD-18558 | biostudies-arrayexpress
Project description:Terminal differentiation is characterized by a respecification of the global protein complement, as epitomized by erythrocytes, whose cytosol is ~98% globin. Remodeling of the proteome involves programmed elimination of generic cellular constituents in parallel with synthesis of cell-type-specific proteins. The erythroid proteome undergoes a rapid transition at the reticulocyte stage; however, the mechanisms driving elimination of preexisting cytosolic proteins are unidentified. UBE2O is a ubiquitin-conjugating enzyme expressed at elevated levels during late stage erythropoiesis. A Ube2o null mutation in mice results in anemia. Proteomic analysis of this mutant suggests that UBE2O is a broad-spectrum ubiquitinating enzyme that remodels the erythroid proteome. In particular, a hallmark of the reticulocyte to mature erythrocyte transition—ribosome elimination—is defective in Ube2o-/- mutants. UBE2O recognizes ribosomal proteins and other substrates directly, targeting them to proteasomes for degradation. Thus, in reticulocytes, and perhaps other highly differentiated cells, the induction of ubiquitinating factors may drive the transition from a complex to a simple proteome.
2017-08-08 | PXD005904 | Pride
Project description:Terminal differentiation of mammalian erythroid progenitors involves 4-5 cell divisions and induction of many erythroid important genes, followed by chromatin and nuclear condensation and enucleation. The protein levels of c-myc (Myc) are reduced dramatically during late stage erythroid maturation, coinciding with cell cycle arrest in G1-phase and enucleation, suggesting possible roles for c-myc in either or both of these processes. Here we demonstrate that ectopic Myc expression affects terminal erythroid maturation in a dose-dependent manner. Expression of Myc at physiological levels did not affect erythroid differentiation or cell cycle shutdown, but specifically blocked erythroid nuclear condensation and enucleation. Myc prevented deacetylation of several lysine residues in histones H3 and H4 that are normally deacetylated during erythroid maturation. When over-expressed at levels higher than the physiological range, Myc blocked erythroid differentiation and the cells continued to proliferate in cytokine-free, serum-containing culture medium with an early erythroblast morphology. These studies reveal an important dose-dependent function of Myc in regulating terminal maturation in mammalian erythroid cells. Our findings further support the emerging notion that Myc regulates chromatin structure by regulating global histone acetylation states.
2010-10-13 | GSE18558 | GEO
Project description:This SuperSeries is composed of the SubSeries listed below.
2021-10-13 | GSE180522 | GEO
Project description:CDAN1, and residue R1042, have a function in DNA replication and organization in terminal erythroid maturation.
2021-03-31 | GSE151476 | GEO
Project description:The NFIA-ETO2 fusion blocks terminal erythroid maturation and induces pure erythroid leukemia (PEL)
| PRJNA844961 | ENA
Project description:Codanin-1 Mutations Engineered in Human Erythroid Cells Demonstrate Role of CDAN1 in Terminal Erythroid Maturation
| PRJNA635926 | ENA
Project description:Global Transcriptome Analyses of Mammalian Terminal Erythroid Differentiation
| PRJNA234281 | ENA